What is the role of botulinum toxin in urinary incontinence treatment?

Updated: Sep 23, 2019
  • Author: Sandip P Vasavada, MD; Chief Editor: Edward David Kim, MD, FACS  more...
  • Print
Answer

A neurotoxin produced by Clostridium botulinum, onabotulinumtoxinA (Botox) prevents acetylcholine release from presynaptic membrane. Therapy for urinary incontinence consists of 30 intradetrusor injections via cystoscopy.

In August 2011, onabotulinumtoxinA was approved by the US Food and Drug Administration (FDA) for urinary incontinence in patients with neurologic conditions (eg, spinal cord injury, multiple sclerosis) who have overactive bladder. Trials have shown patients who received onabotulinumtoxinA had significant reduction in urinary incontinence episodes and improved urodynamics compared with placebo at 12 weeks. [76, 77, 78]  

In January 2013, the FDA expanded the approved use of onabotulinumtoxinA to treat adults with overactive bladder who cannot use or do not adequately respond to anticholinergic drugs. The new indication was based on results of two placebo-controlled clinical trials in 1105 patients with symptoms of overactive bladder. After 12 weeks, patients who received injections of 100 units of onabotulinumtoxinA (20 injections of 5 units each) experienced urinary incontinence an average of 1.6 to 1.9 times less per day than patients treated with placebo. Treatment with onabotulinumtoxinA can be repeated if necessary, but at least 12 weeks should elapse between treatments. [79]

The ABC trial (Anticholinergic therapy vs onabotulinum toxinA for urgency incontinence) shed some light on the utility of 100 units of onabotulinum toxinA in the setting of overactive bladder. The data have shown comparable efficacy of 100 units of onabotulinum toxinA to anticholinergic medications with reduced systemic side effects in the onabotulinum toxinA-injected group, yet higher rates of retention and urinary tract infections. Patients receiving onabotulinum toxinA were more likely to be dry, however. Patients who received anticholinergic drugs were more likely to suffer from dry mouth and other systemic side effects. [80]

In a study that compared sacral neuromodulation and onabotulinumtoxinA in 364 women with refractory urge urinary incontinence, treatment with onabotulinumtoxinA resulted in a greater reduction in 6-month mean number of daily episodes of urge incontinence. However, the authors note that although the difference was statistically significant, is of uncertain clinical importance. In addition, treatment with onabotulinumtoxinA resulted in a higher risk of urinary tract infections and need for transient self-catheterizations. [81]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!